Description
The IDKmonitor® Adalimumab total ADA ELISA measures free and bound antibodies against infliximab.
This assay allows a reliable determination of ADA even in the presence of adalimumab; therefore it is ideal for therapy monitoring when a measurable adalimumab
concentration is expected, for example shortly after the last infusion.
Chronic inflammatory diseases like Crohn’s disease, ulcerative colitis or rheumatoid arthritis are often treated with anti-TNFα antibodies which target directly the underlying inflammatory processes. Therefore, regular monitoring of both the drug level and the formation of antibodies against the drug is important for optimising therapy and the associated long-term therapeutic success.
